STOCK TITAN
  1. Home
  2. Sec-filings
  3. NRIX
  4. [Form 4] Nurix Therapeutics, Inc. Insider Trading Activity

Nurix Therapeutics (NRIX) director awarded 31,250 stock options at $15.86 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nurix Therapeutics director Paul M. Silva received a new stock option grant covering 31,250 shares of Common Stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036.

The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if Silva continues providing service to the company through the vesting date. Following this grant, he holds stock options for 31,250 shares directly.

Positive

  • None.

Negative

  • None.
Insider Silva Paul M
Role null
Type Security Shares Price Value
Grant/Award Director Stock Option (right to buy) 31,250 $0.00 --
Holdings After Transaction: Director Stock Option (right to buy) — 31,250 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 31,250 shares Director stock option award to Paul M. Silva
Exercise price $15.86 per share Director stock option strike price
Expiration date May 14, 2036 Option term end date
Vesting date backstop May 15, 2027 Latest full vesting date, subject to service
Post-grant option holdings 31,250 options Total derivative shares following transaction
Director Stock Option (right to buy) financial
"security_title: Director Stock Option (right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vests financial
"The stock option vests as to 100% of the award"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Silva Paul M
(Last)(First)(Middle)
C/O NURIX THERAPEUTICS, INC.
1600 SIERRA POINT PKWY
(Street)
BRISBANE CALIFORNIA 94005
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director Stock Option (right to buy)$15.8605/15/2026A31,250 (1)05/14/2036Common Stock31,250$031,250D
Explanation of Responses:
1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Remarks:
/s/ Daniel Burbach, as Attorney-in-Fact for Paul M. Silva05/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Nurix Therapeutics (NRIX) disclose about Paul M. Silva in this Form 4?

Nurix Therapeutics reported that director Paul M. Silva received a stock option grant for 31,250 shares of Common Stock at an exercise price of $15.86 per share, expiring May 14, 2036, as part of his director compensation.

How many Nurix Therapeutics (NRIX) options did Paul M. Silva receive and at what price?

Paul M. Silva received options to buy 31,250 shares of Nurix Therapeutics Common Stock at an exercise price of $15.86 per share, giving him the right to purchase those shares at that fixed price until the option’s stated expiration date.

When do Paul M. Silva’s Nurix Therapeutics (NRIX) options vest?

The options vest 100% on the earlier of Nurix Therapeutics’ next annual meeting of stockholders or May 15, 2027. Vesting is conditioned on Silva continuing to provide service to the company on the applicable vesting date.

When do the newly granted Nurix Therapeutics (NRIX) options to Paul M. Silva expire?

The stock options granted to Paul M. Silva expire on May 14, 2036. After that expiration date, the options can no longer be exercised to purchase Nurix Therapeutics Common Stock at the stated $15.86 exercise price.

Is Paul M. Silva’s Form 4 transaction in Nurix Therapeutics (NRIX) an open-market stock purchase?

No, the Form 4 reports a stock option grant categorized as a grant, award, or other acquisition. It is a compensation-related derivative award, not an open-market purchase of Nurix Therapeutics Common Stock for cash.

How many Nurix Therapeutics (NRIX) options does Paul M. Silva hold after this grant?

After this grant, Paul M. Silva holds stock options for 31,250 shares of Nurix Therapeutics Common Stock directly. The filing does not show additional derivative holdings beyond this newly awarded option position.